术中结膜下注射贝伐单抗作为原发性翼状胬肉的辅助治疗：初步报告
Intraoperative subconjunctival bevacizumab as an adjunctive treatment in primary pterygium: a preliminary report.
作者信息
Shahin Maha M, Elbendary Amal M, Elwan Mohamed M
机构信息
Ophthalmology Department, Faculty of Medicine, Mansoura University, Mansoura, Egypt.
出版信息
Ophthalmic Surg Lasers Imaging. 2012 Nov-Dec;43(6):459-66. doi: 10.3928/15428877-20120802-02. Epub 2012 Aug 10.
BACKGROUND AND OBJECTIVE
To evaluate the safety and efficacy of intraoperative subconjunctival bevacizumab as an adjunctive treatment after surgical excision of primary pterygium.
PATIENTS AND METHODS
This was a randomized prospective clinical study. Group 1 (21 eyes) underwent pterygium excision with conjunctivo-limbal autograft. Group 2 (20 eyes) received subconjunctival 1.25 mg/0.05 mL of bevacizumab at the end of the surgery.
RESULTS
There were no statistically significant differences regarding age, sex, laterality, or dimensions of the pterygia or grafts between the two groups (P > .05, 95% confidence interval). After 8 months of follow-up, two eyes in group 1 and four eyes in group 2 had recurrent pterygia. One patient in group 2 had lost graft. The difference in recurrence rate between the two groups did not reach statistical significance (P = 0.4, 95% confidence interval).
CONCLUSION
Intraoperative subconjunctival bevacizumab following primary pterygium surgical excision is not helpful and possibly harmful. Larger studies are needed.
背景与目的
评估术中结膜下注射贝伐单抗作为原发性翼状胬肉手术切除后辅助治疗的安全性和有效性。
患者与方法
这是一项随机前瞻性临床研究。第1组（21只眼）行翼状胬肉切除联合结膜-角膜缘自体移植术。第2组（20只眼）在手术结束时结膜下注射1.25 mg/0.05 mL贝伐单抗。
结果
两组在年龄、性别、患侧、翼状胬肉或移植片大小方面无统计学显著差异（P > 0.05，95%置信区间）。随访8个月后，第1组有2只眼、第2组有4只眼复发翼状胬肉。第2组有1例患者移植片丢失。两组复发率差异无统计学意义（P = 0.4，95%置信区间）。
结论
原发性翼状胬肉手术切除后术中结膜下注射贝伐单抗并无帮助，甚至可能有害。需要开展更大规模的研究。
Zotero 插件